| Print
DiaMedica Therapeutics (DMAC)
Common SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Address
301-1665 Ellis Street
Kelowna
BC
CAN
V1Y 2B3
Telephone
+1 763 4965118
Forecast key dates
| Name | Key Date |
|---|---|
| DiaMedica Therapeutics Inc Third Quarter Earnings Conference Call for 2026 | 2026-11-13T08:00:00 |
| DiaMedica Therapeutics Inc Third Quarter Earnings Results for 2026 | 2026-11-12T00:00:00 |
| DiaMedica Therapeutics Inc Second Quarter Earnings Conference Call for 2026 | 2026-08-13T08:00:00 |
| DiaMedica Therapeutics Inc Second Quarter Earnings Results for 2026 | 2026-08-12T00:00:00 |
| DiaMedica Therapeutics Inc Annual General Meeting for 2026 | 2026-05-15T09:00:00 |
| DiaMedica Therapeutics Inc First Quarter Earnings Conference Call for 2026 | 2026-05-14T08:00:00 |
| DiaMedica Therapeutics Inc First Quarter Earnings Results for 2026 | 2026-05-13T00:00:00 |
| DiaMedica Therapeutics Inc Fourth Quarter Earnings Conference Call for 2025 | 2026-03-18T08:00:00 |
| DiaMedica Therapeutics Inc Fourth Quarter Earnings Results for 2025 | 2026-03-18T00:00:00 |
| DiaMedica Therapeutics Inc Annual Report for 2025 | 2026-03-17T00:00:00 |
Previous key dates
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.